Palvella Therapeutics
PVLA
75 hedge funds and large institutions have $165M invested in Palvella Therapeutics in 2021 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 22 closing their positions.
62% more capital invested
Capital invested by funds: $102M → $165M (+$63M)
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
3% more funds holding
Funds holding: 73 → 75 (+2)
9% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 22
0.07% more ownership
Funds ownership: 0.53% → 0.6% (+0.07%)
15% less call options, than puts
Call options by funds: $1.59M | Put options by funds: $1.88M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$6.54M |
| 2 |
Two Sigma Investments
New York
|
+$5.08M |
| 3 |
Two Sigma Advisers
New York
|
+$4.85M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$3.79M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.94M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.83M |
| 3 |
Renaissance Technologies
New York
|
-$2.22M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$827K |
| 5 |
E
Ergoteles
New York
|
-$796K |
PVLA Hedge Fund Activity: Q3 2021 in Review
75 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2021, worth a combined $165M — up 62% from $102M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PVLA positions and 22 closed out — a net gain of 2 holders — while 17 added to existing stakes and 15 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $6.54M. The largest seller was Millennium Management, cutting an estimated $3.94M.
- 75 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2021, up from 73 in Q2 2021.
- Funds reported $165M of Palvella Therapeutics stock for Q3 2021, up 62% quarter-over-quarter.
- 24 funds opened new Palvella Therapeutics positions in Q3 2021 and 22 closed out, a net change of +2 holders.
- The largest Palvella Therapeutics buyer in Q3 2021 was Invesco, an estimated $6.54M added.
- The largest Palvella Therapeutics seller in Q3 2021 was Millennium Management, an estimated $3.94M sold.
Based on aggregated 13F filings for Q3 2021.